

TABLE OF CONTENTS

<i>Meet the Authors</i>	xv
<i>Dr. Brian M. Kelley</i>	xv
<i>James J. Mahoney, III, M.A.</i>	xvi
<i>John J. Graybeal, M.S.</i>	xvi

CHAPTER 1

INTRODUCTION TO SUBSTANCE ABUSE ACROSS THE LIFESPAN	1
THE BIG QUESTIONS	2
<i>Upon successful completion of this course, the student should be able to do the following</i>	4
<i>These key points, noted above, will be covered in the following chapters</i>	5
TEXT OVERVIEW	6
<i>Welcome to Biopsychosocial Effects of Substances: A Lifespan Approach</i>	6
CHAPTER ONE OVERVIEW	9
<i>Addiction: A Brief History and Current Trends</i>	9
<i>Drug Enforcement Agency Drug Schedules</i>	12
<i>Categorizing Abused Drugs Behaviorally</i>	17
<i>Overview of Addiction</i>	19
<i>Drug Use—An Age-Related Problem</i>	22
<i>Escalation from Use to Abuse</i>	24
<i>Stress and Coping</i>	27
SUMMARY	30
<i>Key Words</i>	31
<i>Case Studies</i>	31
<i>Assessment</i>	31
<i>Ethical and Reflective Question</i>	32
<i>Discussion Questions</i>	32
<i>Application Question</i>	33

CHAPTER 2

BIOLOGICAL BASIS OF SUBSTANCE ABUSE	37
CHAPTER TWO OVERVIEW	37
<i>Interesting Facts About the Brain</i>	37
<i>The Mind-Body or Mind-Brain Problem</i>	38
<i>The Importance of the Neuron</i>	39
<i>Overview of the Axon</i>	41

<i>Overview of the Synapse and the Dendrite</i>	42
<i>Review of Neuronal Communication</i>	43
INTRODUCTION TO THE CENTRAL NERVOUS SYSTEM	44
<i>Spinal Cord</i>	47
<i>Medulla</i>	49
<i>Pons</i>	49
<i>Midbrain</i>	51
<i>Thalamus</i>	52
<i>Hypothalamus</i>	53
<i>Hippocampus</i>	54
<i>Amygdala</i>	55
<i>Insular Cortex</i>	56
<i>Cerebellum</i>	57
<i>Cerebral Cortex</i>	59
<i>Frontal Lobe</i>	59
<i>Prefrontal Cortex</i>	60
<i>Parietal Lobe</i>	62
<i>Occipital Lobe</i>	62
<i>Temporal Lobe</i>	62
<i>In Conclusion</i>	63
SUMMARY	63
<i>Key Words</i>	64
<i>Case Studies</i>	64
<i>Assessment</i>	64
<i>Ethical and Reflective Question</i>	65
<i>Discussion Questions</i>	66
<i>Application Question</i>	67
 CHAPTER 3	
PHARMACOLOGY AND TOXICOLOGY	69
CHAPTER THREE OVERVIEW	69
<i>Why Does a Person Abuse Drugs?</i>	69
<i>Introduction to Pharmacology</i>	69
<i>Chemical Properties</i>	71
<i>Biological Factors</i>	71
<i>Pharmacokinetics</i>	72
<i>Absorption</i>	73
<i>Route of Administration and Learning</i>	74
<i>Oral Route</i>	75
<i>Mucous Membranes, Which Includes Buccal/Sublingual and Intranasal</i>	76
<i>Intravenous Injection</i>	76

<i>Intramuscular Injection</i>	77
<i>Inhalation</i>	77
<i>Transdermal Infusion</i>	78
<i>Drug Distribution</i>	79
<i>Health and Medical Consequences</i>	80
<i>Cardiovascular System</i>	80
<i>Respiratory System</i>	80
<i>Gastrointestinal System</i>	81
<i>Musculoskeletal System</i>	81
<i>Neurobiological and Behavioral Systems</i>	81
<i>Endocrine and Reproductive Systems</i>	81
<i>The Immune System</i>	81
<i>Renal System</i>	81
<i>Hepatic System</i>	82
<i>Cell Growth and Repair (i.e., Cancer)</i>	82
<i>Metabolism and Elimination</i>	82
<i>Time Course of Drug Effects</i>	83
<i>Sex Differences in Metabolism and Elimination</i>	84
<i>Cross Tolerance</i>	84
<i>Elimination</i>	84
<i>Pharmacodynamics</i>	84
SUMMARY	88
<i>Key Words</i>	88
<i>Case Studies</i>	88
<i>Assessment</i>	89
<i>Ethical and Reflective Question</i>	89
<i>Discussion Questions</i>	90
<i>Application Question</i>	91

CHAPTER 4

SUBSTANCE ABUSE AS A DEVELOPMENTAL DISORDER	93
CHAPTER FOUR OVERVIEW	93
<i>Facts and Statistics on Adolescent Drug Use (CASA, 2011)</i>	93
INTRODUCTION	94
<i>Development</i>	95
<i>Pregnancy and Fetal and Developmental Outcomes</i>	96
<i>Teen Drug Use</i>	99
<i>Development of the Limbic System: Reward and Risk Taking</i>	106
<i>Cognitive Psychology and the Frontal Lobe</i>	110
<i>Frontal Lobe Development</i>	110
<i>Functions of the Frontal Lobe</i>	111

<i>Attention and Automaticity</i>	111
<i>Drugs and the Frontal Lobe</i>	113
<i>Elderly</i>	116
SUMMARY	116
<i>Case Studies</i>	117
<i>Assessment</i>	117
<i>Ethical and Reflective Question</i>	118
<i>Discussion Questions</i>	118
<i>Application Question</i>	120
 CHAPTER 5	
SUBSTANCE ABUSE: A DISORDER OF LEARNING	121
CHAPTER FIVE OVERVIEW	121
<i>Perceiving Drug Effects</i>	122
<i>Introduction to Sensations and Perceptions</i>	125
<i>In Summary</i>	126
<i>The Common Pathway of the Sensory Systems: From Receptor to Awareness</i>	127
<i>Organization of Sensory Pathways</i>	130
<i>Measuring the Perceptual Effects of Abused Drugs</i>	131
<i>Understanding Unconscious Learning</i>	133
<i>Music as a Stepping-Stone</i>	134
<i>Learning to Be an Addict</i>	135
<i>Generalization and Discrimination</i>	137
<i>Focus on Operant Conditioning</i>	138
<i>Punishment</i>	139
<i>Schedules of Reinforcement</i>	140
<i>Focus on Classical Conditioning</i>	142
<i>Temporal Conditioning</i>	143
<i>The Role of Timing in Learning</i>	144
<i>Summary of Learning Processes</i>	146
<i>Timing: Reward versus Punishment</i>	146
<i>Cycle of Drug Use and Addiction</i>	147
SUMMARY	149
<i>Key Words</i>	150
<i>Case Studies</i>	150
<i>Assessment</i>	150
<i>Ethical and Reflective Question</i>	151
<i>Discussion Questions</i>	151
<i>Application Question</i>	152

CHAPTER 6

INTRODUCTION TO DRUGS WITH DEPRESSANT PROPERTIES	155
CHAPTER SIX OVERVIEW	155
ALCOHOL	155
<i>History</i>	155
<i>Quick Overview of the Problem</i>	157
<i>Mechanism of Action</i>	157
<i>Every Single Organ is Negatively Impacted by Alcohol</i>	161
<i>Alcohol-Related Injuries</i>	163
<i>Alcohol and Sex and Sexual Assault</i>	165
<i>Alcohol and College Students</i>	166
<i>Temporal Effects of Alcohol</i>	166
<i>Sex Differences in Alcohol Consumption</i>	169
<i>Alcohol and Caffeine</i>	169
<i>Alcohol, Caffeine, and the Subjective Experience</i>	171
<i>Alcohol, Energy Drinks, and Underage Youth</i>	172
INHALANTS	175
<i>Inhalant Abuse</i>	176
<i>How Serious Is the Problem?</i>	177
<i>Why Are Inhalants Abused?</i>	177
<i>Characteristics of the User</i>	177
<i>Signs of Acute Use</i>	178
<i>Signs of Chronic Use</i>	178
<i>Effects on Organ Systems</i>	178
<i>Where Do We Go from Here?</i>	179
BARBITURATES	179
<i>History</i>	179
BENZODIAZEPINES	182
<i>History</i>	182
NEUROPSYCHOLOGICAL CONSEQUENCES OF DEPRESSANT USE	185
SUMMARY	187
<i>Key Words</i>	187
<i>Case Studies</i>	187
<i>Assessment</i>	187
<i>Ethical and Reflective Question</i>	188
<i>Discussion Questions</i>	188
<i>Application Question</i>	189

CHAPTER 7

INTRODUCTION TO DRUGS WITH STIMULANT PROPERTIES	191
CHAPTER SEVEN OVERVIEW	191
NICOTINE	191
<i>History</i>	191
<i>Tobacco Products</i>	193
<i>Clinical Application: Focus on Adolescent Tobacco Cessation</i>	195
COCAINE, AMPHETAMINE, AND METHAMPHETAMINE	201
<i>Cocaine</i>	202
<i>Amphetamine</i>	205
<i>Methamphetamine</i>	206
PRESCRIPTION STIMULANTS	208
ECSTASY (MDMA)	209
<i>History</i>	209
<i>Mephedrone ("Bath Salts")</i>	210
NEUROPSYCHOLOGICAL CONSEQUENCES OF STIMULANT USE	213
SUMMARY	215
<i>Key Words</i>	215
<i>Case Studies</i>	215
<i>Assessment</i>	215
<i>Ethical and Reflective Question</i>	216
<i>Discussion Questions</i>	217
<i>Application Question</i>	217

CHAPTER 8

INTRODUCTION TO MARIJUANA, HALLUCINOGENS AND PAINKILLERS	219
CHAPTER EIGHT OVERVIEW	219
MARIJUANA	219
<i>History</i>	219
<i>Abuse and Dependence Defined</i>	222
<i>Neuropsychological Consequences of Use</i>	226
<i>Synthetic Marijuana (i.e., "Spice" or "K2")</i>	228
LSD	230
<i>History</i>	230
PCP AND OTHER HALLUCINOGENS	232
<i>PCP</i>	232
<i>Ketamine and Dextromethorphan</i>	233
<i>Scopolamine and Mescaline</i>	235

NARCOTICS AND HEROIN	236
<i>Opium History</i>	236
NEUROPSYCHOLOGICAL CONSEQUENCES OF OPIOID USE	241
SUMMARY	242
<i>Key Words</i>	243
<i>Case Studies</i>	243
<i>Assessment</i>	243
<i>Ethical and Reflective Question</i>	244
<i>Discussion Questions</i>	244
<i>Application Question</i>	245

CHAPTER 9

DIAGNOSING AND TREATING SUBSTANCE ABUSE PROBLEMS 247

CHAPTER NINE OVERVIEW	247
<i>Diagnosing Drug Abuse Problems</i>	247
<i>Matching Patients to Programs</i>	249
<i>Using Research to Help Patients</i>	251
<i>Treating Substance Abuse</i>	251
<i>Various Treatment Strategies</i>	251
<i>Easy to Use</i>	252
<i>Reasonable and Responsive</i>	253
<i>Fluid and Flexible</i>	253
<i>Utilizing Cognitive Behavioral Techniques for Substance Dependence</i>	254
<i>Cognitive Behavioral Therapy + Contingency Management for Substance Dependence</i>	255
<i>Cognitive Behavioral Therapy Plus Virtual Reality Exposure for Substance Dependence</i>	257
<i>Published and Current Research Involving Cognitive Behavioral Therapy and Substance Dependence</i>	258
<i>Limitations Associated with Cognitive Behavioral Therapy</i>	261
<i>Future Directions for Cognitive Behavioral Therapy and Substance Dependence</i>	262
<i>Clinical Application: Focus on Adult Tobacco Cessation</i>	263
<i>Tobacco Use and Treatment in the Primary Care Environment</i>	263
<i>The Clinical Practice Guideline for the Treatment of Tobacco Use and Dependence</i>	265
<i>Relapse</i>	265
<i>Epidemiology and Demographics</i>	266
SUMMARY	267
<i>Key Words</i>	268
<i>Case Studies</i>	268

<i>Assessment</i>	268
<i>Ethical and Reflective Question</i>	269
<i>Discussion Questions</i>	269

CHAPTER 10

RECOGNIZING RISK AND SUBSTANCE ABUSE PREVENTION 271

CHAPTER TEN OVERVIEW	271
<i>Health and Medical Problems</i>	271
<i>Psychological Factors</i>	273
<i>Comorbidity: Self-Medication</i>	273
<i>Dealing with Special Populations</i>	278
<i>A Detailed Look at Homelessness: Rochester, NY</i>	279
<i>Social Factors</i>	281
<i>Music, Memories, Movies, and Drug Use</i>	282
<i>Drug Abuse As a Social Problem</i>	287
<i>Parents: The Number One Prevention Resource</i>	290
<i>The Science of Prevention</i>	290
SUMMARY	298
<i>Key Words</i>	299
<i>Case Studies</i>	299
<i>Assessment</i>	299
<i>Ethical and Reflective Question</i>	300
<i>Discussion Questions</i>	300
<i>Application Question</i>	301

STUDY AIDS 303

CHAPTER ONE: INTRODUCTION TO SUBSTANCE ABUSE ACROSS THE LIFESPAN	303
<i>Chapter One Answers</i>	303
CHAPTER TWO: BIOLOGICAL BASIS OF SUBSTANCE ABUSE	303
<i>Chapter Two Answers</i>	303
CHAPTER THREE: PHARMACOLOGY AND TOXICOLOGY	303
<i>Chapter Three Answers</i>	304
CHAPTER FOUR: SUBSTANCE ABUSE AS A DEVELOPMENTAL DISORDER	304
<i>Chapter Four Answers</i>	304
CHAPTER FIVE: SUBSTANCE ABUSE: A DISORDER OF LEARNING	304
<i>Chapter Five Answers</i>	304
CHAPTER SIX: INTRODUCTION TO DRUGS WITH DEPRESSANT PROPERTIES	304

<i>Chapter Six Answers</i>	305
CHAPTER SEVEN: INTRODUCTION TO DRUGS WITH STIMULANT PROPERTIES	305
<i>Chapter Seven Answers</i>	305
CHAPTER EIGHT: INTRODUCTION TO MARIJUANA, HALLUCINOGENS, AND PAINKILLERS	305
<i>Chapter Eight Answers</i>	305
CHAPTER NINE: DIAGNOSING AND TREATING SUBSTANCE ABUSE PROBLEMS	305
<i>Chapter Nine Answers</i>	305
CHAPTER TEN: RECOGNIZING RISK AND SUBSTANCE ABUSE PREVENTION	306
<i>Chapter Ten Answers</i>	306
TOP WEBSITES FOR SUBSTANCE ABUSE INFORMATION	306
AAAP—American Academy of Addiction Psychology	306
ASAM—American Society on Addiction Medicine	306
ASAP—Army Substance Abuse Program	306
CADCA—Community Anti-Drug Coalitions of America	307
CADCA Institute—CADCA's National Coalition Institute	307
CASA—The National Center on Addiction and Substance Abuse at Columbia University	307
CDC—Centers for Disease Control and Prevention	307
CEDAR—Center for Education and Drug Abuse Research	307
CMHS—Center for Mental Health Services	308
The College on Problems of Drug Dependence	308
CSAP—Center for Substance Abuse Prevention	308
CSAT—Center for Substance Abuse Treatment	308
DARE—Drug Abuse Resistance Education	308
DATOS—Drug Abuse Treatment Outcome Studies	308
DEA—Drug Enforcement Agency	309
DFC—Drug Free Communities Support Program	309
DHHS—United States Department of Health and Human Services	309
DOJ—Department of Justice	309
Drug Strategies	309
EDC—Education Development Center, Health and Human Development Division	309
ISAP—Integrated Substance Abuse Program	310
Legacy	310
NAADAC—The Association for Addiction Professionals	310
NCA—National Coalition Academy	310
NCADD—National Council on Alcoholism and Drug Dependence, Inc.	310

<i>NIAAA—National Institute on Alcohol Abuse and Alcoholism</i>	311
<i>NIDA—National Institute on Drug Abuse</i>	311
<i>NIH—National Institutes of Health</i>	311
<i>NYLI—National Youth Leadership Initiative</i>	311
<i>OJJDP—Office of Juvenile Justice and Delinquency Prevention</i>	311
<i>ONDCP—Executive Office of the President, Office of National Drug Control Policy</i>	311
<i>RAND Corporation</i>	312
<i>SAMHDA—Substance Abuse and Mental Health Data Archive</i>	312
<i>SAMHSA—Substance Abuse and Mental Health Services Administration</i>	312
<i>ScienceDaily</i>	312
<i>SPF—Strategic Prevention Framework</i>	312

REFERENCES 313